Monoclonal antibody PR1
Alternative Names: PR1Latest Information Update: 24 Oct 2021
At a glance
- Originator National Cancer Institute (USA)
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Prostate cancer